These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28378174)

  • 1. Rapidly progressive IgA nephropathy.
    Kobayashi N; Nishida M; Aoyama M; Yokoi K; Yahata T; Oka T; Sakata K; Shiraishi I; Itoi T; Hamaoka K
    Indian J Pediatr; 2005 Mar; 72(3):257-260. PubMed ID: 28378174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidly progressive IgA nephropathy.
    Kobayashi N; Nishida M; Aoyama M; Yokoi K; Yahata T; Tatsujiro T; Sakata K; Shiraishi I; Itoi T; Hamaoka K
    Indian J Pediatr; 2005 Mar; 72(3):257-60. PubMed ID: 15812125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retrospective study of primary IgA nephropathy with crescent formation and/or rapidly progressive glomerulonephritis in children].
    Wang D; Wang F; Ding J; Xiao H; Zhong X; Liu X
    Zhonghua Er Ke Za Zhi; 2015 Sep; 53(9):670-5. PubMed ID: 26757967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic IgA nephropathy with diffuse crescent formation.
    Tang Z; Wu Y; Wang QW; Yu YS; Hu WX; Yao XD; Chen HP; Liu ZH; Li LS
    Am J Nephrol; 2002; 22(5-6):480-6. PubMed ID: 12381947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological analysis of IgA nephropathy with crescentic formation in childhood].
    Yao Y; Liu JC; Xiao HJ; Huang JP; Yang JY
    Zhonghua Er Ke Za Zhi; 2004 Jun; 42(6):412-6. PubMed ID: 15265422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy.
    Fujinaga S; Ohtomo Y; Umino D; Mochizuki H; Murakami H; Shimizu T; Yamashiro Y; Kaneko K
    Pediatr Nephrol; 2007 Jun; 22(6):899-902. PubMed ID: 17285293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-reperfusion rapidly progressive glomerulonephritis in post-transplant IgA nephropathy.
    Tovbin D; Shnaider A; Kachko L; Basok A; Vorobiov M; Rogachev B; Abramov D; Zlotnik M
    J Nephrol; 2004; 17(1):130-3. PubMed ID: 15151270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation.
    Tang Z; Ji SM; Chen DR; Wen JQ; Chen JS; Liu ZH; Li LS
    Ren Fail; 2008; 30(6):611-6. PubMed ID: 18661411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute renal failure in the course of IgA nephropathy in a 16-year-old boy].
    Bilińska W; Rogowska-Kalisz A; Nowicki M
    Pol Merkur Lekarski; 2003 Apr; 14(82):340-1. PubMed ID: 12868197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapidly Progressive Glomerulonephritis Secondary to IgA Nephropathy in a Patient with Systemic Lupus Erythematosus.
    Patel AM; Karam LAR; Rojas SCF; Redfearn WE; Truong LD; Gonzalez JM
    Case Rep Nephrol; 2019; 2019():8354823. PubMed ID: 30956828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of childhood IgA nephropathy who developed rapidly progressive glomerulonephritis in one-year clinical course].
    Motoyama O; Nagai Y; Hasegawa A; Hirata K; Kawamura S; Iitaka K
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):615-21. PubMed ID: 1920941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute kidney injury in immunoglobulin A nephropathy: potential role of macroscopic hematuria and acute tubulointerstitial injury.
    Kveder R; Lindic J; Ales A; Kovac D; Vizjak A; Ferluga D
    Ther Apher Dial; 2009 Aug; 13(4):273-7. PubMed ID: 19695058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and pathological manifestations of Chinese childhood patients with primary IgA nephropathy: a national collaborative study of 33 hospitals].
    ; Jiang XY
    Zhonghua Er Ke Za Zhi; 2007 Apr; 45(4):272-8. PubMed ID: 17706064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy].
    Sugawara K; Takeda K; Nakai K; Takahashi N; Adachi T; Fukuda T; Miura S
    Nihon Jinzo Gakkai Shi; 2008; 50(8):1017-23. PubMed ID: 19172803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of membranous nephropathy to acute crescentic rapidly progressive glomerulonephritis and response to pulse methylprednisolone.
    Koethe JD; Gerig JS; Glickman JL; Sturgill BC; Bolton WK
    Am J Nephrol; 1986; 6(3):224-8. PubMed ID: 3740132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
    Ishii T; Kawamura T; Tsuboi N; Ogura M; Utsunomiya Y; Hosoya T
    Contrib Nephrol; 2007; 157():114-9. PubMed ID: 17495447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature.
    Lai KN; Lai FM; Leung AC; Ho CP; Vallance-Owen J
    Am J Kidney Dis; 1987 Jul; 10(1):66-70. PubMed ID: 3300287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria.
    Hoshino Y; Kaga T; Abe Y; Endo M; Wakai S; Tsuchiya K; Nitta K
    Clin Exp Nephrol; 2015 Oct; 19(5):918-24. PubMed ID: 25672293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of rapidly progressive IgA nephropathy with transient hypocomplementemia at onset].
    Yamazaki Y; Mori A; Nomura Y; Satoh A; Park KI; Kawakatsu H; Nishida M
    Nihon Jinzo Gakkai Shi; 1997 Oct; 39(7):765-70. PubMed ID: 9396246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of rapidly progressive IgA nephropathy in a patient with exacerbation of Crohn's disease.
    Choi JY; Yu CH; Jung HY; Jung MK; Kim YJ; Cho JH; Kim CD; Kim YL; Park SH
    BMC Nephrol; 2012 Aug; 13():84. PubMed ID: 22866754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.